BR9911068A - Terapia combinada para tratamento de distúrbios bipolares - Google Patents

Terapia combinada para tratamento de distúrbios bipolares

Info

Publication number
BR9911068A
BR9911068A BR9911068-7A BR9911068A BR9911068A BR 9911068 A BR9911068 A BR 9911068A BR 9911068 A BR9911068 A BR 9911068A BR 9911068 A BR9911068 A BR 9911068A
Authority
BR
Brazil
Prior art keywords
treatment
bipolar disorders
combination therapy
bipolar
depression
Prior art date
Application number
BR9911068-7A
Other languages
English (en)
Inventor
Gary Dennis Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9911068A publication Critical patent/BR9911068A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Patente de Invenção: <B>"TERAPIA COMBINADA PARA TRATAMENTO DE DISTúRBIOS BIPOLARES"<D>. A presente invenção propicia métodos e composições para o tratamento de Distúrbio Bipolar, Depressão Bipolar ou Depressão Unipolar, todas essas com ou sem características psicóticas. Este método emprega um composto dotado de atividade como um antipsicótico atípico e um inibidor da reabsorção de serotonina.
BR9911068-7A 1998-05-29 1999-05-21 Terapia combinada para tratamento de distúrbios bipolares BR9911068A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8712698P 1998-05-29 1998-05-29
PCT/US1999/011314 WO1999062522A1 (en) 1998-05-29 1999-05-21 Combination therapy for treatment of bipolar disorders

Publications (1)

Publication Number Publication Date
BR9911068A true BR9911068A (pt) 2001-02-06

Family

ID=22203275

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911068-7A BR9911068A (pt) 1998-05-29 1999-05-21 Terapia combinada para tratamento de distúrbios bipolares

Country Status (19)

Country Link
EP (1) EP0966967A3 (pt)
JP (1) JP2002516864A (pt)
KR (1) KR20010043731A (pt)
CN (1) CN1302207A (pt)
AU (1) AU756468B2 (pt)
BR (1) BR9911068A (pt)
CA (1) CA2332408A1 (pt)
CZ (1) CZ20004280A3 (pt)
EA (1) EA003611B1 (pt)
HR (1) HRP20000798A2 (pt)
HU (1) HUP0102511A2 (pt)
IL (1) IL139591A0 (pt)
NO (1) NO20005884L (pt)
NZ (1) NZ507981A (pt)
PL (1) PL344304A1 (pt)
SK (1) SK17492000A3 (pt)
TR (1) TR200003525T2 (pt)
WO (1) WO1999062522A1 (pt)
ZA (1) ZA200006817B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6174882B1 (en) * 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
FR2802101B1 (fr) * 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
EP1309325A1 (en) * 2000-08-02 2003-05-14 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション
CA2445528A1 (en) * 2001-04-26 2002-11-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
AU2003291720A1 (en) * 2002-11-01 2004-06-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
CN1989968B (zh) 2002-12-27 2011-05-11 大塚制药株式会社 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
US20050038036A1 (en) * 2003-05-16 2005-02-17 Pfizer Inc Treatment of bipolar disorders and associated symptoms
CN102166359A (zh) * 2003-05-23 2011-08-31 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
WO2005053703A1 (en) 2003-12-02 2005-06-16 Leslie James Sheldon Combination therapy for dementia, depression and apathy
EP1696896A2 (en) * 2003-12-15 2006-09-06 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
CA2569411A1 (en) * 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EP2453024B1 (en) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
CA2629299C (en) 2005-11-12 2017-08-22 The Board Of Trustees Of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
EP2026790A2 (en) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
US20080199866A1 (en) * 2006-10-10 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University Snp detection and other methods for characterizing and treating bipolar disorder and other ailments
GB0814466D0 (en) * 2008-08-07 2008-09-10 Rosemont Pharmaceuticals Ltd Sertraline composition
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN108926569A (zh) * 2018-08-24 2018-12-04 山西医科大学第医院 一种非典型抗精神病药物组合物
CN109464436A (zh) * 2019-01-10 2019-03-15 高智玉 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用
CN110151718A (zh) * 2019-06-13 2019-08-23 厦门医学院 一种奥氮平口腔崩解片及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8072691A (en) * 1990-06-28 1992-01-23 Beecham Group Plc Pharmaceutical preparations
WO1997033577A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Method for treating bipolar disorder
WO1997035586A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
TR200003525T2 (tr) 2001-04-20
IL139591A0 (en) 2002-02-10
NO20005884L (no) 2001-01-24
HUP0102511A2 (hu) 2001-11-28
AU4008899A (en) 1999-12-20
CN1302207A (zh) 2001-07-04
JP2002516864A (ja) 2002-06-11
WO1999062522A1 (en) 1999-12-09
SK17492000A3 (sk) 2002-04-04
AU756468B2 (en) 2003-01-16
EP0966967A3 (en) 2000-05-31
EA200001244A1 (ru) 2001-06-25
ZA200006817B (en) 2002-02-21
EP0966967A2 (en) 1999-12-29
CA2332408A1 (en) 1999-12-09
PL344304A1 (en) 2001-10-22
NZ507981A (en) 2003-10-31
NO20005884D0 (no) 2000-11-21
CZ20004280A3 (cs) 2001-09-12
HRP20000798A2 (en) 2001-10-31
EA003611B1 (ru) 2003-06-26
KR20010043731A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
BR9911068A (pt) Terapia combinada para tratamento de distúrbios bipolares
FI963294A0 (fi) Naftyyliamidit keskushermostoaineina
BRPI0414794A (pt) oxadiazolidinadionas substituìdas
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
MY134110A (en) Combinations of reboxetine and neuroleptic agents
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
AU1850801A (en) The combination of a serotonin reuptake inhibitor and irindalone
ATE380029T1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
BRPI0415409A (pt) uso de efetuadores de ciclases de glutaminila e glutamato
BR0208373A (pt) Inibidores da tirosina cinase
BR9911049A (pt) Terapia combinada para tratamento de depressão resistente
BR0011172A (pt) Derivados do 4,5-diaril-3(2h)-furanona como inibidores de cliclooxigenase-2
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
BRPI0408477A (pt) compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
BRPI0507250A (pt) combinações para tratar desordens do snc
BRPI0414049A (pt) compostos e composições como inibidores de proteìna cinase
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.